Followers | 10 |
Posts | 1578 |
Boards Moderated | 0 |
Alias Born | 10/15/2014 |
Monday, May 15, 2017 10:33:49 AM
The revenue is truly ridiculous.
I run a well funded substance abuse/mental health field program. I work with psychiatrists and specializing doctors in this field. From single providers to organizations, I have first hand knowledge in diagnosing, stabilizing and qualifying a patient for the implant. The problems with the implant are as follows:
1. Patient inquires or is made aware of implant. Patient learns he/she has to have a stable dosage of suboxone first before implant. This process can be immediate if the patient is on maintenance or it can take weeks or even months!
2. Approval of the implant. Doctors were provided a 3-4 page application by Braeburn pharmaceuticals for authorization of implant. If you were lucky, it got approved right away (>5% of the time). Once you get initial denial, you contest the findings. The insurance company doctor and the requesting doctor hold a phone conversation regarding medical necessity of implant. This has a success rate of 50-60%. If this gets denied you file another dispute and you get the same conversation with a different independent doctor that holds the final ruling. This has a 60-80% success rate. Now this whole process of authorization is just for implant. A separate authorization is required for the actual procedure itself. Similar process but a bit less of a hassle.
3. Billing: doctors initially had no clue how to bill. They were given a self help booklet by Braeburn Pharmaceuticals but that didn't help. The J CODE used for billing initially was a $25 payout by Blue Shield and Anthem. The doctors were being paid similar to routine procedures and months late. Add to the hassle is That the patient has a 50% copay and if not the HMO plans literally might pay $10 for the implant procedure. Lets say provider is out of network But doctors don't know how much to charge since no one knows the industry set standard amount yet.
Insurance companies were not ready for the implant nor was Braeburn Pharmaceuticals. The launch was a mess. The first few months, the doctors were having a difficult time getting their certificate of procedure uploaded online for FDA approval to actually get the implants sent to. My providers were one of the first few to put the actual imlants. I have personally been involved in the approval with at least 5 patients.
Recent TTNP News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:33:11 PM
- Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria • GlobeNewswire Inc. • 01/25/2024 09:29:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:59:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 10:13:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:30:20 PM
- Titan Pharmaceuticals Announces Reverse Stock Split and Ratio • GlobeNewswire Inc. • 12/28/2023 09:15:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2023 09:47:46 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/17/2023 09:03:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 09:05:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:33:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:31:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:29:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:25:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:23:37 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 10/24/2023 09:26:34 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/23/2023 07:07:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 09:08:35 PM
- Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors • GlobeNewswire Inc. • 10/16/2023 08:37:23 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 10/04/2023 09:30:18 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 09/19/2023 08:41:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2023 08:45:22 PM
- Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock • GlobeNewswire Inc. • 09/18/2023 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 09:30:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2023 08:28:25 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM